U.S. markets closed
  • S&P 500

    4,686.75
    +95.08 (+2.07%)
     
  • Dow 30

    35,719.43
    +492.40 (+1.40%)
     
  • Nasdaq

    15,686.92
    +461.76 (+3.03%)
     
  • Russell 2000

    2,253.79
    +50.31 (+2.28%)
     
  • Crude Oil

    71.73
    +2.24 (+3.22%)
     
  • Gold

    1,784.90
    +5.40 (+0.30%)
     
  • Silver

    22.52
    +0.26 (+1.18%)
     
  • EUR/USD

    1.1273
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.4800
    +0.0460 (+3.21%)
     
  • GBP/USD

    1.3239
    -0.0021 (-0.16%)
     
  • USD/JPY

    113.5800
    +0.0900 (+0.08%)
     
  • BTC-USD

    50,248.07
    -281.27 (-0.56%)
     
  • CMC Crypto 200

    1,308.39
    -12.89 (-0.98%)
     
  • FTSE 100

    7,339.90
    +107.62 (+1.49%)
     
  • Nikkei 225

    28,455.60
    +528.23 (+1.89%)
     

ARK ETF Investors Not Getting Seasick

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The big question earlier in the year, as the high-flying performance of ARK’s ETFs began descending to earth only to land in choppy seas, was whether investors would hold on in these rough waters.

While year-to-date performance of the ARK Funds has been disappointing, at least relative to SPY, the issuer has had no trouble continuing to gain and maintain assets as it navigates turbulent seas.

 

ARK Flows
ARK Flows

Source: FactSet

(For a larger view, click on the image above)

 

(Use our Fund Flows tool to find an ETF’s flows for a specific time period.)

 

Several of the ARK funds have picked up well over $1 billion so far this year. The ARK Innovation ETF (ARKK) has seen nearly $6.5 billion in net flows.

The two funds that have gained the most assets so far this year, ARKK and the ARK Genomic Revolution ETF (ARKG), are the two worst-performing funds of the bunch, with year-to-date returns in negative territory.

 

Chart courtesy of StockCharts.com

 

Flagship Fund Falters

ARKK, the issuer’s flagship fund, which holds $22.6 billion in assets, had been up more than 25% in February before beginning its downward trend. The fund holds a portfolio of global stocks that are involved with or benefit from disruptive innovation.

ARKK is concentrated in software, biotech and IT services, with these industries making up about 50% of the portfolio. ARKK is relatively concentrated, with over half of the holdings in the top 10 and only holding 50 stocks in total.

 

Pop-up Image
Pop-up Image

Source: FactSet

(For a larger view, click on the image above)

 

With concentrated portfolios, there is a higher risk of volatility, as there is less diversification to smooth out returns should some of the holdings underperform.

Of the top 10 holdings, several have been significant detractors from the fund’s return for the year-to-date. Teladoc Health, Unity Software and Spotify are down anywhere from 16% to 33% so far this year.

 

Chart courtesy of StockCharts.com

 

The one thing all of these stocks have in common is that their stock prices ran up significantly in 2020, benefiting from the stay-at-home trade.

 

(Use our stock finder tool to find an ETF’s allocation to a certain stock.)

 

With revenue growth slowing in 2021, and investors focusing on stocks that would benefit from reopening, the shine has come off these names.

Biotech Names Bumble

ARKG has fared even worse this year, falling by 11.9% year-to-date after having gained more than 20% in mid-February. The $8.5 billion fund has a more focused mandate versus ARKK’s, targeting companies involved in the genomics industry.

Similar to ARKK, the fund is highly concentrated, with 43% of the portfolio in the top 10, and 59 holdings in total.

 

ARKG Top 10
ARKG Top 10

Source: FactSet

(For a larger view, click on the image above)

 

Nearly half of the fund is in biotechnology names. In a similar story to ARKK’s, many of the top holdings have had double-digit losses this year.

Teladoc is a top holding in this ETF as well. Other names such as Exact Sciences, Ionis Pharmaceuticals and Twist Bioscience are all down nearly 30% for the year.

 

Chart courtesy of StockCharts.com

 

Biotech names are generally a riskier and more volatile area of the market, with stocks in this space often depending on binary outcomes. For example, Ionis Pharmaceuticals’ stock fell nearly 22% in one day in mid-March after its partner, Roche Holding, announced plans to stop treating patients with Ionis’ drug, tominersen.

Yields Weigh On Growth Names

Aside from stock-specific risk, these ETFs have also been subject to downward pressure from the sharp increase in the U.S. 10-year Treasury yield, particularly in the early spring months.

 

Source: FactSet

 

Yields nearly doubled from the beginning of the year through the end of the first quarter. Growth stocks, like the ones favored by ARK, are negatively affected by rising rates.

Growth stocks tend to command premium valuations due to the promise of higher growth in the future. However, rising rates—meaning more expensive borrowing and higher levels of inflation—eat into these future cash flows, putting downward pressure on prices.

Time Horizon Important

As mentioned above, concentrated portfolios such as those run by Cathie Wood and team are particularly prone to volatility. However, widening the lens and looking at the long term can help remind investors of the importance of staying patient.

 

Chart courtesy of StockCharts.com

 

Over the trailing three years, the three largest ARK funds have more than doubled the performance of the SPDR S&P 500 ETF Trust (SPY), even after accounting for their lackluster performance this year.

Though past performance is no indication of future results, it seems most investors in these ETFs are all hands on deck and holding course, betting that history will repeat itself.

Contact Jessica Ferringer at jessica.ferringer@etf.com or follow her on Twitter

Recommended Stories


Permalink | © Copyright 2021 ETF.com. All rights reserved